LY294002 inhibits glucocorticoid-induced COX-2 gene expression in cardiomyocytes through a phosphatidylinositol 3 kinase-independent mechanism

Toxicology and Applied Pharmacology

Volumn 232, Issue 1, 2008, Pages 25-32

  Sun, Haipeng ^a   Xu, Beibei ^b   Sheveleva, Elena ^b   Chen, Qin M ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Calcium; Cyclooxygenase; Phosphatidylinositol 3 kinase inhibitors

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2 PIPERAZINYL 8 PHENYL 4H 1 BENZOPYRAN 4 ONE; BENZOPYRAN DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CASEIN KINASE II; COMPLEMENTARY DNA; CORTICOSTERONE; CYCLOOXYGENASE 2; DNA DEPENDENT PROTEIN KINASE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; LUCIFERASE; LY 303511; MAMMALIAN TARGET OF RAPAMYCIN; NIMODIPINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM ION; RNA; TETRYLAMMONIUM; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME ASSAY; GENE EXPRESSION; HEART MUSCLE CELL; NEWBORN; NONHUMAN; PROMOTER REGION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANIMALS; ANIMALS, NEWBORN; CALCIUM; CALCIUM CHANNEL BLOCKERS; CHROMONES; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; GLUCOCORTICOIDS; MORPHOLINES; MYOCYTES, CARDIAC; NIMODIPINE; PIPERAZINES; POTASSIUM CHANNEL BLOCKERS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; TETRAETHYLAMMONIUM; TIME FACTORS;

MAMMALIA; RATTUS;

EID: 51549110734     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.05.024     Document Type: Article

References (58)

1. Adcock I.M., Ito K., and Barnes P.J. Glucocorticoids: effects on gene transcription. Proc. Am. Thorac. Soc. 1 (2004) 247-254
2. Adderley S.R., and Fitzgerald D.J. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J. Biol. Chem. 274 (1999) 5038-5046
3. Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., and Hemmings B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15 (1996) 6541-6551
4. Bachelor M.A., Cooper S.J., Sikorski E.T., and Bowden G.T. Inhibition of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase decreases UVB-induced activator protein-1 and cyclooxygenase-2 in a SKH-1 hairless mouse model. Mol. Cancer Res. 3 (2005) 90-99
5. Bolli R., Shinmura K., Tang X.L., Kodani E., Xuan Y.T., Guo Y., and Dawn B. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc. Res. 55 (2002) 506-519
6. Calabresi L., Rossoni G., Gomaraschi M., Sisto F., Berti F., and Franceschini G. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ. Res. 92 (2003) 330-337
7. Camitta M.G.W., Gabel S.A., Chulada P., Bradbury J.A., Langenbach R., Zeldin D.C., and Murphy E. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation 104 (2001) 2453-2458
8. Chen Q.M., Alexander D., Sun H., Xie L., Lin Y., Terrand J., Morrissy S., and Purdom S. Corticosteroids inhibit cell death induced by doxorubicin in cardiomyocytes: induction of antiapoptosis, antioxidant, and detoxification genes. Mol. Pharm. 67 (2005) 1861-1873
9. Chen Q.M., Bartholomew J.C., Campisi J., Acosta M., Reagan J.D., and Ames B.N. Molecular analysis of H2O2-induced senescent-like growth arrest in normal human fibroblasts: p53 and Rb control G1 arrest but not cell replication. Biochem. J. 332 (1998) 43-50
10. Choi E.-K., Park H.-J., Ma J.-S., Lee H.-C., Kang H.-C., Kim B.-G., and Kang I.-C. LY294002 inhibits monocyte chemoattractant protein-1 expression through a phosphatidylinositol 3-kinase-independent mechanism. FEBS Lett. 559 (2004) 141-144
11. Choudhary S., Kumar A., Kale R.K., Raisz L.G., and Pilbeam C.C. Extracellular calcium induces COX-2 in osteoblasts via a PKA pathway. Biochem. Biophys. Res. Comm. 322 (2004) 395-402
12. Coronella-Wood J., Terrand J., Sun H., and Chen Q.M. c-Fos phosphorylation induced by H2O2 prevents proteasomal degradation of c-Fos in cardiomyocytes. J. Biol. Chem. 279 (2004) 33567-33574
13. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
14. Doi S., Damron D.S., Ogawa K., Tanaka S., Horibe M., and Murray P.A. K(+) channel inhibition, calcium signaling, and vasomotor tone in canine pulmonary artery smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol. 279 (2000) L242-251
15. El-Kholy W., Macdonald P.E., Lin J.H., Wang J., Fox J.M., Light P.E., Wang Q., Tsushima R.G., and Wheeler M.B. The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks K(V) currents via a direct mechanism. FASEB J. 17 (2003) 720-722
16. Elliott E.M., and Sapolsky R.M. Corticosterone impairs hippocampal neuronal calcium regulation-possible mediating mechanisms. Brain Res. 602 (1993) 84-90
17. Ethier M.F., and Madison J.M. LY294002, but not wortmannin, increases intracellular calcium and inhibits calcium transients in bovine and human airway smooth muscle cells. Cell Calcium 32 (2002) 31-38
18. Fomina A.F., Kostyuk P.G., and Sedova M.B. Glucocorticoid modulation of calcium currents in growth hormone 3 cells. Neuroscience 55 (1993) 721-725
19. Hafezi-Moghadam A., Simoncini T., Yang Z., Limbourg F.P., Plumier J.C., Rebsamen M.C., Hsieh C.M., Chui D.S., Thomas K.L., Prorock A.J., Laubach V.E., Moskowitz M.A., French B.A., Ley K., and Liao J.K. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat. Med. 8 (2002) 473-479
20. Hara K., Yonezawa K., Sakaue H., Ando A., Kotani K., Kitamura T., Kitamura Y., Ueda H., Stephens L., Jackson T.R., et al. 1-Phosphatidylinositol 3-kinase activity is required for insulin-stimulated glucose transport but not for RAS activation in CHO cells. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 7415-7419
21. Hinz B., and Brune K. Cyclooxygenase-2-10 years later. J. Pharm. Exp. Therap. 300 (2002) 367-375
22. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., Huang Q., Qin J., and Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127 (2006) 125-137
23. Jerde T.J., Mellon W.S., Bjorling D.E., Checura C.M., Owusu-Ofori K., Parrish J.J., and Nakada S.Y. Stretch induction of cyclooxygenase-2 expression in human urothelial cells is calcium- and protein kinase C zeta-dependent. Mol. Pharm. 73 (2008) 18-26
24. Kim Y.H., Choi K.-H., Park J.-W., and Kwon T.K. LY294002 inhibits LPS-induced NO production through a inhibition of NF-[kappa]B activation: independent mechanism of phosphatidylinositol 3-kinase. Immun. Lett. 99 (2005) 45-50
25. Kristof A.S., Pacheco-Rodriguez G., Schremmer B., and Moss J. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms. J. Pharm. Exp. Therap. 314 (2005) 1134-1143
26. Layne E. Spectrophotometric and turbidimetric methods for measuring proteins. Meth. Enzymol. 3 (1957) 447-454
27. Levitan E.S., Hershman K.M., Sherman T.G., and Takimoto K. Dexamethasone and stress upregulate Kv1.5 K+ channel gene expression in rat ventricular myocytes. Neuropharmacology 35 (1996) 1001-1006
28. Ma X.Q., Fu R.F., Feng G.Q., Wang Z.J., Ma S.G., and Weng S.A. Hypoxia-reoxygenation-induced apoptosis in cultured neonatal rat cardiomyocyets and the protective effect of prostaglandin E. Clin. Exp. Pharm. Physiol. 32 (2005) 1124-1130
29. Oudit G.Y., Sun H., Kerfant B.G., Crackower M.A., Penninger J.M., and Backx P.H. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J. Mol. Cell Cardiol. 37 (2004) 449-471
30. Pasapera Limon A.M., Herrera-Munoz J., Gutierrez-Sagal R., and Ulloa-Aguirre A. The phosphatidylinositol 3-kinase inhibitor LY294002 binds the estrogen receptor and inhibits 17[beta]-estradiol-induced transcriptional activity of an estrogen sensitive reporter gene. Mol. Cell. Endocrinol. 200 (2003) 199-202
31. Pham H., Shafer L.M., and Slice L.W. CREB-dependent cyclooxygenase-2 and microsomal prostaglandin E synthase-1 expression is mediated by protein kinase C and calcium. J. Cell. Biochem. 98 (2006) 1653-1666
32. Pino M., Nawrocki S., Cognetti F., Abruzzese J., Xiong H., and McConkey D. Prostaglandin E(2) drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. Cancer Biol. Therapy 4 (2005) 1263-1269
33. Poh T.W., and Pervaiz S. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res. 65 (2005) 6264-6274
34. Puga A., Hoffer A., Zhou S., Bohm J.M., Leikauf G.D., and Shertzer H.G. Sustained increase in intracellular free calcium and activation of cyclooxygenase-2 expression in mouse hepatoma cells treated with dioxin. Biochem. Pharm. 54 (1997) 1287-1296
35. Purdom-Dickinson S., Sheveleva E., HP S., and Chen Q. Translational control of Nrf2 protein in activation of antioxidant response element by oxidants. Mol. Pharm. 72 (2007) 1074-1081
36. Purdom S., and Chen Q.M. Epidermal growth factor receptor-dependent and -independent pathways in hydrogen peroxide-induced mitogen-activated protein kinase activation in cardiomyocytes and heart fibroblasts. J. Pharm. Exp. Therap. 312 (2005) 1179-1186
37. Sah R., Oudit G.Y., Nguyen T.T., Lim H.W., Wickenden A.D., Wilson G.J., Molkentin J.D., and Backx P.H. Inhibition of calcineurin and sarcolemmal Ca2+ influx protects cardiac morphology and ventricular function in K(v)4.2N transgenic mice. Circulation 105 (2002) 1850-1856
38. Sheu M.L., Ho F.M., Yang R.S., Chao K.F., Lin W.W., Lin-Shiau S.Y., and Liu S.-H. High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. Arterioscler Thromb. Vasc. Biol. 25 (2005) 539-545
39. Shimoni Y. Dexamethasone and cardiac potassium currents in the diabetic rat. Brit. J. Pharm. 146 (2005) 280-287
40. Shinmura K., Tamaki K., Sato T., Ishida H., and Bolli R. Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H2093-2101
41. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Ann. Rev. Biochem. 69 (2000) 145-182
42. Straube S., and Parekh A.B. Effects of phosphatidylinositol kinase inhibitors on the activation of the store-operated calcium current ICRAC in RBL-1 cells. Pflugers Arch. 442 (2001) 391-395
43. Sun H., Oudit G.Y., Ramirez R.J., Costantini D., and Backx P.H. The phosphoinositide 3-kinase inhibitor LY294002 enhances cardiac myocyte contractility via a direct inhibition of Ik, slow currents. Cardiovasc. Res. 62 (2004) 509-520
44. Sun, H., Xu, B.B., Sheveleva, E., Chen, Q.M., in press. p38 MAPK mediates COX-2 gene expression by corticosterone in cardiomyocytes. Cell. Signal.
45. Tahara S., Fukuda K., Kodama H., Kato T., Miyoshi S., and Ogawa S. Potassium channel blocker activates extracellular signal-regulated kinases through Pyk2 and epidermal growth factor receptor in rat cardiomyocytes. J. Am. Coll. Cardiol. 38 (2001) 1554-1563
46. Tang Q., Gonzales M., Inoue H., and Bowden G.T. Roles of Akt and glycogen synthase kinase 3{beta} in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes. Cancer Res. 61 (2001) 4329-4332
47. Tokuno T., Muraki K., Watanabe M., and Imaizumi Y. Effects of K+ channel modulators on the relationship between action potential duration and Ca2+ transients in single ventricular myocytes of the guinea pig. Jpn. J. Pharm. 80 (1999) 243-253
48. Tu V.C., Bahl J.J., and Chen Q.M. Signals of oxidant-induced cardiomyocyte hypertrophy: key activation of p70 S6 kinase-1 and phosphoinositide 3-kinase. J. Pharm. Exp. Therap. 300 (2002) 1101-1110
49. Turini M., and DuBois R. Cyclooxygenase-2: a therapeutic target. Ann. Rev. Med. 53 (2002) 35-57
50. Vanhaesebroeck B., Leevers S.J., Ahmadi K., Timms J., Katso R., Driscoll P.C., Woscholski R., Parker P.J., and Waterfield M.D. Synthesis and function of 3-phosphorylated inositol lipids. Ann. Rev. Biochem. 70 (2001) 535-602
51. Vlahos C.J., Matter W.F., Hui K.Y., and Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269 (1994) 5241-5248
52. Walker E.H., Pacold M.E., Perisic O., Stephens L., Hawkins P.T., Wymann M.P., and Williams R.L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell. 6 (2000) 909-919
53. Wang Y., Cheng J., Tandan S., Jiang M., McCloskey D.T., and Hill J.A. Transient-outward K+ channel inhibition facilitates L-type Ca2+ current in heart. J. Cardiovasc. Electrophysiol. 17 (2006) 298-304
54. Warner T., and Mitchell J. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 18 (2004) 790-804
55. Welling A., Hofmann F., and Wegener J.W. Inhibition of L-type Cav1.2 Ca2+ channels by 2,(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) and 2-[1-(3-dimethyl-aminopropyl)-5-methoxyindol-3-yl]-3-(1H-indol-3-yl) maleimide (Go6983). Mol. Pharm. 67 (2005) 541-544
56. Wu W., Silbajoris R.A., Whang Y.E., Graves L.M., Bromberg P.A., and Samet J.M. p38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for Zn2+-induced cyclooxygenase-2 expression. Am. J. Physiol. Lung Cell. Mol. Physiol. 289 (2005) L883-889
57. Xiao C.Y., Yuhki K., Hara A., Fujino T., Kuriyama S., Yamada T., Takayama K., Takahata O., Karibe H., Taniguchi T., Narumiya S., and Ushikubi F. Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation 109 (2004) 2462-2468
58. Xuan Y.-T., Guo Y., Zhu Y., Wang O.-L., Rokosh G., Messing R.O., and Bolli R. Role of the protein kinase C-{epsilon}-Raf-1-MEK-1/2-p44/42 MAPK signaling cascade in the activation of signal transducers and activators of transcription 1 and 3 and induction of cyclooxygenase-2 after ischemic preconditioning. Circulation 112 (2005) 1971-1978